Home > Products > CD3 & EGFR
> Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (scIgG)
Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (scIgG) (CAT#: SCIGG-077)
Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-EGFR IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (scIgG) (SCIGG-077). Click the button below to contact us or submit your feedback about this product.